Trump Signs Executive Order to Fast-Track Psychedelic Drug Approvals
20 Apr 2026 · 12:33 UTC · CoinCentral RSS Feed · Original source
Read original at CoinCentral RSS Feed →
Summary
President Trump signed an executive order directing the FDA to accelerate reviews of psychedelic drugs for mental health treatment. The order grants Commissioner's National Priority Vouchers to psychedelic drugs designated as breakthrough therapies, reducing review periods from 6-10 months to 1-2 months. Pharmaceutical companies Atai Beckley and Compass Pathways saw significant stock price increases of 28% and 26% respectively in premarket trading following the announcement.
Why it matters
This executive order targets FDA pharmaceutical approval timelines for psychedelic drugs, affecting biotech firms exclusively. There is no direct connection to cryptocurrency. The indirect pathway would require: pharmaceutical news → improved market sentiment → increased risk appetite → crypto buying. However, this chain is weak because pharmaceutical regulatory news has low salience for crypto traders. Altcoins show slightly higher potential sensitivity than Bitcoin due to greater overall volatility and sentiment responsiveness, but the base effect remains marginal. Longer timeframes have marginally higher impact probability due to accumulation of indirect sentiment effects, but these remain speculative and uncertain. Publication on a crypto news platform, rather than a financial or biotech news platform, suggests editorial judgment that may prioritize engagement over relevance, reducing credibility as crypto analysis.
Expected impact
This article concerns FDA pharmaceutical regulatory policy and biotech stocks (Atai Beckley, Compass Pathways), not cryptocurrency. The executive order accelerating psychedelic drug approvals has no direct mechanism affecting Bitcoin or altcoin markets. Any crypto impact would be indirect and minimal, potentially through marginal improvements in overall risk sentiment if pharmaceutical approval acceleration boosts market confidence in regulatory processes. However, pharmaceutical news ranks low as a driver of crypto trading decisions relative to macro economic data, Fed policy, or crypto-specific regulation. Publication on CoinCentral (a crypto news site) appears to be off-topic content that may mislead investors seeking relevant cryptocurrency market information.